294 related articles for article (PubMed ID: 25018107)
21. Preclinical evaluation of [(18)F]JNJ42259152 as a PET tracer for PDE10A.
Celen S; Koole M; Ooms M; De Angelis M; Sannen I; Cornelis J; Alcazar J; Schmidt M; Verbruggen A; Langlois X; Van Laere K; Andrés JI; Bormans G
Neuroimage; 2013 Nov; 82():13-22. PubMed ID: 23664955
[TBL] [Abstract][Full Text] [Related]
22. [18F]JNJ42259152 binding to phosphodiesterase 10A, a key regulator of medium spiny neuron excitability, is altered in the presence of cyclic AMP.
Ooms M; Attili B; Celen S; Koole M; Verbruggen A; Van Laere K; Bormans G
J Neurochem; 2016 Dec; 139(5):897-906. PubMed ID: 27664396
[TBL] [Abstract][Full Text] [Related]
23. Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo.
Van Laere K; Casteels C; Dhollander I; Goffin K; Grachev I; Bormans G; Vandenberghe W
J Nucl Med; 2010 Sep; 51(9):1413-7. PubMed ID: 20720046
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease.
Giampà C; Laurenti D; Anzilotti S; Bernardi G; Menniti FS; Fusco FR
PLoS One; 2010 Oct; 5(10):e13417. PubMed ID: 20976216
[TBL] [Abstract][Full Text] [Related]
25. Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's disease.
Kleiman RJ; Kimmel LH; Bove SE; Lanz TA; Harms JF; Romegialli A; Miller KS; Willis A; des Etages S; Kuhn M; Schmidt CJ
J Pharmacol Exp Ther; 2011 Jan; 336(1):64-76. PubMed ID: 20923867
[TBL] [Abstract][Full Text] [Related]
26. In vitro phosphodiesterase 10A (PDE10A) binding in whole hemisphere human brain using the PET radioligand [
Svedberg MM; Varnäs K; Varrone A; Mitsios N; Mulder J; Gulyás B; Beaumont V; Munoz-Sanjuan I; Zaleska MM; Schmidt CJ; Halldin C; Mrzljak L
Brain Res; 2019 May; 1711():140-145. PubMed ID: 30664847
[TBL] [Abstract][Full Text] [Related]
27. Patterns of brain glucose metabolism induced by phosphodiesterase 10A inhibitors in the mouse: a potential translational biomarker.
Dedeurwaerdere S; Wintmolders C; Vanhoof G; Langlois X
J Pharmacol Exp Ther; 2011 Oct; 339(1):210-7. PubMed ID: 21742809
[TBL] [Abstract][Full Text] [Related]
28. Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice.
Dowie MJ; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
Neuroscience; 2010 Sep; 170(1):324-36. PubMed ID: 20600638
[TBL] [Abstract][Full Text] [Related]
29. Characterization of the binding properties of T-773 as a PET radioligand for phosphodiesterase 10A.
Harada A; Suzuki K; Miura S; Hasui T; Kamiguchi N; Ishii T; Taniguchi T; Kuroita T; Takano A; Stepanov V; Halldin C; Kimura H
Nucl Med Biol; 2015 Feb; 42(2):146-54. PubMed ID: 25451212
[TBL] [Abstract][Full Text] [Related]
30. PDE10 inhibition increases GluA1 and CREB phosphorylation and improves spatial and recognition memories in a Huntington's disease mouse model.
Giralt A; Saavedra A; Carretón O; Arumí H; Tyebji S; Alberch J; Pérez-Navarro E
Hippocampus; 2013 Aug; 23(8):684-95. PubMed ID: 23576401
[TBL] [Abstract][Full Text] [Related]
31. Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice.
McCaw EA; Hu H; Gomez GT; Hebb AL; Kelly ME; Denovan-Wright EM
Eur J Biochem; 2004 Dec; 271(23-24):4909-20. PubMed ID: 15606779
[TBL] [Abstract][Full Text] [Related]
32. Quantification of 18F-JNJ-42259152, a novel phosphodiesterase 10A PET tracer: kinetic modeling and test-retest study in human brain.
Van Laere K; Ahmad RU; Hudyana H; Dubois K; Schmidt ME; Celen S; Bormans G; Koole M
J Nucl Med; 2013 Aug; 54(8):1285-93. PubMed ID: 23843566
[TBL] [Abstract][Full Text] [Related]
33. Molecular and behavioral analysis of the R6/1 Huntington's disease transgenic mouse.
Naver B; Stub C; Møller M; Fenger K; Hansen AK; Hasholt L; Sørensen SA
Neuroscience; 2003; 122(4):1049-57. PubMed ID: 14643771
[TBL] [Abstract][Full Text] [Related]
34. Brain Diffusivity and Structural Changes in the R6/2 Mouse Model of Huntington Disease.
Vorisek I; Syka M; Vargova L
J Neurosci Res; 2017 Jul; 95(7):1474-1484. PubMed ID: 27726161
[TBL] [Abstract][Full Text] [Related]
35. Preclinical evaluation of 18F-JNJ41510417 as a radioligand for PET imaging of phosphodiesterase-10A in the brain.
Celen S; Koole M; De Angelis M; Sannen I; Chitneni SK; Alcazar J; Dedeurwaerdere S; Moechars D; Schmidt M; Verbruggen A; Langlois X; Van Laere K; Andrés JI; Bormans G
J Nucl Med; 2010 Oct; 51(10):1584-91. PubMed ID: 20847170
[TBL] [Abstract][Full Text] [Related]
36. Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors.
Glass M; van Dellen A; Blakemore C; Hannan AJ; Faull RL
Neuroscience; 2004; 123(1):207-12. PubMed ID: 14667455
[TBL] [Abstract][Full Text] [Related]
37. The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease.
Hickey MA; Reynolds GP; Morton AJ
J Neurochem; 2002 Apr; 81(1):46-59. PubMed ID: 12067237
[TBL] [Abstract][Full Text] [Related]
38. Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease.
Bisogno T; Martire A; Petrosino S; Popoli P; Di Marzo V
Neurochem Int; 2008 Jan; 52(1-2):307-13. PubMed ID: 17664017
[TBL] [Abstract][Full Text] [Related]
39. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
Lastres-Becker I; Hansen HH; Berrendero F; De Miguel R; Pérez-Rosado A; Manzanares J; Ramos JA; Fernández-Ruiz J
Synapse; 2002 Apr; 44(1):23-35. PubMed ID: 11842443
[TBL] [Abstract][Full Text] [Related]
40. Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease.
Laprairie RB; Bagher AM; Kelly ME; Denovan-Wright EM
Mol Pharmacol; 2016 Mar; 89(3):364-75. PubMed ID: 26700564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
